Clinical Trial: Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07651007) titled 'Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR' on June 11.

Brief Summary: The goal of this clinical trial is conducted to evaluate the neoadjuvant regimen of short-course radiotherapy (SCRT) followed by NALIRIFOX chemotherapy plus Pucotenlimab immunotherapy for high-risk locally advanced rectal cancer.

The main questions it aims to answer are:

1. Does this regimen increase the complete response rate ?

2. What medical problems (adverse events) do participants have when receiving this treatment? Researchers will evaluate this regimen compare...